Barclays analyst Christopher Pasquale is watching this opportunity, and he lays out a positive outlook for the sector as a whole. In a note earlier this month, Pasquale lays out a case for buying in, ...

Fintel reports that on October 7, 2026, Barclays initiated coverage of Insulet (BIT:1PODD) with a Equal-Weight recommendation. This action follows a prior action on May 8, 2026, when Barclays ...

A cross-sectional study of 16,267 insulin-requiring adults across 40 federally qualified health centers in 17 states found ...

Fintel reports that on October 7, 2026, Barclays initiated coverage of Tandem Diabetes Care, Inc. - Depositary Receipt (BOVESPA:T2ND34) with an Equal-Weight recommendation. Tandem Diabetes Care, Inc., ...

Beta Bionics now carries an updated fair value estimate of US$23.80 per share, up from about US$21.67, which refines how ...

A cross-sectional study of 1,532 non-diabetic adults in Turkey found that the triglyceride-to-HDL cholesterol ratio and ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its ...

Coding approvals reflect growing clinical evidence and physician adoption of Medtronic solutions addressing urge urinary ...

For years, TFEB has been regarded as one of the most promising therapeutic targets for restoring the cell's ability to clear ...

Most diabetes care is delivered in primary care, but barriers to access and adoption of diabetes technologies remain.

DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data ...

Sheila Denton "brings deep board experience, strong regulatory and transactional judgment, and a proven ability to lead ...